Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients with a confirmed diagnosis of bilateral benign essential blepharospasm, and having symptoms of such for at least 6 months prior to the baseline visit
naïve patients to botulinum toxin type A treatment, or patients who had received a single treatment of botulinum toxin type A, or those who had demonstrated a satisfactory response, in the investigator's opinion, to the last 2 injections of botulinum toxin type A with a minimum of 12 weeks since the last injection and where a further injection at full dosage was now indicated
patients with a minimum score of 8 on the BDS
You may not be if
patients with either neuroleptic-induced blepharospasm, isolated levator dysfunction or apraxia
previous surgical, chemical and thermal myectomy or neurectomy
any condition where intramuscular injection is contraindicated
ophthalmolgical infection
myasthenia gravis or other disorders of the neuromuscular junction
prescription of antispastic, muscle relaxants or medications affecting neuromuscular junction transmission, or medication where the dose or choice of medication has not been constant for the last 30 days
Clareo Health | Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
